NASDAQ:SRZN

Surrozen (SRZN) Stock Price, News & Analysis

$8.97
-0.04 (-0.44%)
(As of 04/24/2024 ET)
Today's Range
$8.59
$9.84
50-Day Range
$8.97
$15.71
52-Week Range
$4.50
$16.19
Volume
8,980 shs
Average Volume
17,048 shs
Market Capitalization
$28.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Surrozen MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Surrozen in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$3 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($9.19) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

515th out of 907 stocks

Biological Products, Except Diagnostic Industry

82nd out of 154 stocks

SRZN stock logo

About Surrozen Stock (NASDAQ:SRZN)

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

SRZN Stock Price History

SRZN Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Surrozen Provides Corporate Update on Clinical Programs
3 Biotech Stocks to Watch in November
Surrozen Provides Third Quarter 2023 Financial Results
Surrozen Inc Ordinary Shares SRZN
Surrozen GAAP EPS of -$0.31
See More Headlines
Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/24/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRZN
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Net Income
$-43,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.50 million
Book Value
$18.39 per share

Miscellaneous

Free Float
2,079,000
Market Cap
$28.70 million
Optionable
Not Optionable
Beta
0.74
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Craig C. Parker M.B.A. (Age 62)
    CEO, President & Director
    Comp: $753.3k
  • Mr. Charles Williams (Age 43)
    CFO, COO & Corporate Secretary
    Comp: $563.49k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisor
  • Dr. Roeland Nusse Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisor
  • Dr. Calvin Kuo M.D.
    Ph.D., Co-Founder & Member of Scientific Advisor
  • Dr. Li Yang Ph.D.
    Executive Vice President of Research
  • Esther Jhun
    Controller

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed in 2024?

Surrozen's stock was trading at $9.40 at the beginning of the year. Since then, SRZN stock has decreased by 4.6% and is now trading at $8.97.
View the best growth stocks for 2024 here
.

Are investors shorting Surrozen?

Surrozen saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,900 shares, an increase of 132.4% from the March 15th total of 3,400 shares. Based on an average trading volume of 17,800 shares, the short-interest ratio is presently 0.4 days. Currently, 0.6% of the shares of the stock are sold short.
View Surrozen's Short Interest
.

When is Surrozen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our SRZN earnings forecast
.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) announced its earnings results on Monday, November, 15th. The company reported ($7.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.85) by $1.80.

When did Surrozen's stock split?

Surrozen shares reverse split before market open on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRZN) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners